Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that Dr. Judith van Deutekom, Prosensa’s Vice President of Drug Discovery, has been awarded a $200,000 research grant from Parent Project Muscular Dystrophy (PPMD), the… Continue reading Prosensa Awarded $200,000 Research Grant from PPMD
Blog posts
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the successful completion of enrollment in its prospective Natural History Study designed to increase the understanding of Duchenne muscular dystrophy (DMD). The study enrolled… Continue reading Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
Prosensa’s Hans Schikan Appointed to the Biotechnology Industry Organization’s Emerging Companies Section Governing Board
San Diego, CA, June 23, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Hans GCP Schikan, Chief Executive Officer of Prosensa, has been appointed to the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board.
Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD
Plans to Submit a New Drug Application to the FDA this Year; Dialogue with EMA continues with intent to seek approval Leiden, The Netherlands, June 3, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that the United States… Continue reading Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD
Mucosis Receives Financial Support from the Dutch Government for its SynGEM® Program
Groningen, the Netherlands, May 22, 2014 – Biotechnology company Mucosis B.V. today announced that it has received an innovation credit line of up to €5 million from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use these funds to further advance the clinical development of its proprietary SynGEM®… Continue reading Mucosis Receives Financial Support from the Dutch Government for its SynGEM® Program
